重视胰腺癌诊治的全流程管理

doi:10.3969/j.issn.1009-976X.2021.01.001

岭南现代临床外科 ›› 2021, Vol. 21 ›› Issue (01): 1-5.DOI: 10.3969/j.issn.1009-976X.2021.01.001

• 专家笔谈 • 下一篇

重视胰腺癌诊治的全流程管理

楼文晖

复旦大学附属中山医院胰腺外科、复旦大学附属中山医院肿瘤防治中心,上海 200032

通讯作者: 楼文晖,Email：lou.wenhui@zs_hospital.sh.cn
作者简介:楼文晖,医学博士，主任医师，教授，博士生导师
复旦大学附属中山医院胰腺外科主任、普外科副主任、外科中心实验室主任。上海市优秀学科带头人，上海医学会普外科分会前任主任委员。现任上海医学会外科分会副主任委员，中华医学会第十八届外科委员会全国委员、中华医学会外科学分会胰腺外科学组副组长、中国研究型医院协会胰腺病分会副会长、中国医师协会外科分会全国委员、中国医师协会胰腺病专业委员会常委，MDT专业委员会常委；神经内分泌肿瘤分委会主任委员；中国医促会神经内分泌肿瘤分会、快速康复委员会、减重及代谢外科分会副会长；中国医学装备协会外科装备分会基础装备专委会主任委员。《岭南现代临床外科》杂志副主编、《Journal of Digestive Disease》、《Annual of Surgery》（中文版）、《中国实用外科杂志》、《中华肝胆外科杂志》，《中华医学杂志》、《中华外科杂志》、《中华消化外科杂志》的编委和通讯编委。
近年来以第一作者和通讯作者在国内核心期刊和国外杂志发表文章一百多篇，其中SCI论文六十余篇。承担多项包括国家自然科学基金，“863”项目、国家重大研发计划等多项国家级和省市级研究课题。2020年获得上海医学二等奖、先后获得“国之名医”（2019年），上海市杰出专科医师（2020年）等称号。
基金资助:
国家自然科学基金（81773068）; 科技部国家重点研发计划（2019YFC1315902）

Whole disease journey management in the diagnosis and treatment of pancreatic cancer

LOU Wen-hui

Department of Pancreatic Surgery, Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Online:2021-02-20 Published:2021-04-08

摘要/Abstract

摘要： 胰腺癌的发病率逐年增高,远期疗效不佳,为了改善胰腺癌的预后,有必要推进以疾病为中心的诊疗模式,通过多学科团队的有机组合,达成早期诊断、分期、精准治疗、合理手术、对症支持治疗的全诊治流程管理,时刻跟踪和应用多组学分析、肿瘤免疫、靶向治疗和放化疗的最新进展,显著提高胰腺癌的远期疗效。

关键词: 胰腺癌, 诊断, 治疗, 精准医学

Abstract: The incidence of pancreatic cancer is increasing quickly, with dismal prognosis. In order to improve the long-term survival of pancreatic cancer, it is necessary to employ the disease-centered multidisciplinary model in the diagnosis and treatment. Via effective combination of multidisciplinary team to achieve the whole journey management of diagnosis, staging, precision medicine, rational operation, and supportive care. Improvement of long-term survival could be accomplished as new advances of multi-omics, tumor immunology, target therapy and chemo-radiation therapy.

Key words: pancreatic cancer, diagnosis, treatment, precision medicine

中图分类号:

R735.9

楼文晖. 重视胰腺癌诊治的全流程管理[J]. 岭南现代临床外科, 2021, 21(01): 1-5.

LOU Wen-hui. Whole disease journey management in the diagnosis and treatment of pancreatic cancer[J]. Lingnan Modern Clinics In Surgery, 2021, 21(01): 1-5.

参考文献

[1] Liu H, Sun B, Wang S, et al.Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma[J]. Cell Physiol Biochem, 2017, 42(1):373-382.
[2] Sausen M, Phallen J, Adleff V, et al.Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients[J]. Nat Commun, 2015, 6:7686.
[3] Liu X, Liu L, Ji Y, et al.Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer[J]. EbioMedicine, 2019, 41:345-356.
[4] Yang Z, LaRiviere MJ, Ko J, et al. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma[J]. Clin Cancer Res, 2020, 26(13):3248-3258.
[5] Khorana AA, Mangu PB, Berlin J, et al.Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2016, 34(21):2541-2556.
[6] Attiyeh MA, Chakraborty J, Doussot A, et al.Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis[J]. Ann Surg Oncol, 2018, 25(4):1034-1042.
[7] DreyerSB, PineseM, JamiesonNB, et al. Precision oncology in surgery: patient selection for operable pancreatic cancer[J].Ann Surg, 2020, 272(2):366-376.
[8] Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages[J]. PLoS Med, 2010, 7(4):e1000267.
[9] National Comprehensive Cancer Network.(NCCN) Clinical PracticeGuidelinesinOncology.PancreaticAdenocarcinoma,Version3 [EB/OL].[2019-11-27]. https://www.nccn.org/professionals/physician_gls/default.aspx.
[10] Paula G, Daniel H.Palmer, et al. ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer[J]. J Clin Oncol, 2020, 38(15_suppl): 4504-4504.
[11] Davendra S, Mai T.Duong, et al. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA)[J]. J Clin Oncol, 2020, 38(15_suppl): 4504-4504.
[12] Chad A Barnes, Ashley N Krepline, Mohammed Aldakkak, et al.Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?[J]. J Gastrointest Surg, 2017, 21(11):1793-1803.
[13] Santucci N, Facy O, Ortega-Deballon P,et al.CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients[J]. Pancreatology, 2018, 18(6):666-670.
[14] Tsai S, George B, Wittmann D,et al.Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients with Localized Pancreatic Cancer[J]. Ann Surg, 2020, 271(4):740-747.
[15] Pishvaian MJ, Bender RJ, Halverson D, et al.Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative[J]. Clin Cancer Res, 2018, 24(20):5018-5027.
[16] Golan T, Hammel P, Reni M, et al.Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4):317-327.
[17] B Schultheis, D Reuter, MP Ebert, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study[J]. Ann Oncol,2017,28(10):2429-2435.
[18] Gemenetzis G, Groot VP, Yu J, et al.Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate with Disease Status: Results of the Prospective CLUSTER Study[J]. Ann Surg, 2018, 268(3):408-420.

重视胰腺癌诊治的全流程管理

Whole disease journey management in the diagnosis and treatment of pancreatic cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	何冲, 周姝睿, 李雅晴, 陈少杰, 练国达, 陈尚祥, 黄开红. 胰腺癌预后相关铁死亡基因筛选及预后预测模型构建[J]. 岭南现代临床外科, 2022, 22(1): 14-23.
[2]	林杏仪, 田振烽, 潘乐乐, 苏铭昕, 陈茵婷. 基于GEO数据库的胰腺癌循环肿瘤细胞代谢通路及关键基因研究[J]. 岭南现代临床外科, 2022, 22(1): 34-41.
[3]	刘伟. 恶性脑胶质瘤单放和放化疗临床疗效5年随诊分析[J]. 岭南现代临床外科, 2022, 22(1): 89-93.
[4]	黄沾任, 宁金月, 李汉卿, 陈念平. 免疫联合靶向治疗在晚期肝癌转化治疗中的研究进展[J]. 岭南现代临床外科, 2022, 22(1): 110-114.
[5]	孔令启, 屈艳琳, 朱凡河. 小儿睾丸肿瘤的诊疗现状[J]. 岭南现代临床外科, 2021, 21(06): 684-687.
[6]	吴卓鹏, 杨劼. 胸外科手术后继发乳糜胸的防治[J]. 岭南现代临床外科, 2021, 21(06): 688-692.
[7]	鲁旭, 李华, 易述红, 赵辉, 朱曙光, 李海波, 杨扬, 汪国营. 介入联合仑伐替尼桥接治疗超米兰标准肝癌肝移植2例报道[J]. 岭南现代临床外科, 2021, 21(05): 507-511.
[8]	黄国辉, 刘燕萍, 王声燕, 张龙. 脾转移性肿瘤56例临床病理分析[J]. 岭南现代临床外科, 2021, 21(05): 526-530.
[9]	林志文, 刘红枝, 曾永毅. 肝内胆管癌淋巴结清扫的热点与争议[J]. 岭南现代临床外科, 2021, 21(04): 377-382.
[10]	关健华, 温坚坤, 林启谋, 黄文俊. 手术切除联合植入缓释型5-FU在局部区域复发的乳腺癌患者中的应用分析（附27例病例数据分析）[J]. 岭南现代临床外科, 2021, 21(04): 428-431.
[11]	冯惠仪, 吴明玮. 非小细胞肺癌EGFR罕见突变及其靶向与免疫治疗策略[J]. 岭南现代临床外科, 2021, 21(04): 482-488.
[12]	付佳禄, 雷建军, 张东, 耿智敏. 胆囊癌新辅助治疗研究现状[J]. 岭南现代临床外科, 2021, 21(03): 257-264.
[13]	丁陈陈, 宋兴东, 张磊. 肝脏外科医生眼中的2021 ASCO[J]. 岭南现代临床外科, 2021, 21(03): 265-271.
[14]	杨文倩, 林婉宜, 龚畅. 乳腺癌肝转移特征及诊疗[J]. 岭南现代临床外科, 2021, 21(03): 272-277.
[15]	高振华, 王军宏, 万玉萍, 邵娥玲, 王兴胜, 钱宏亮, 吕鹏翔, 冉亚伟. 自身免疫性胰腺炎临床治疗体会[J]. 岭南现代临床外科, 2021, 21(03): 329-332.